ラテンアメリカのg-Csf/Peg-G-Csf市場のトレンドと業界成長2030年まで

ラテンアメリカのG-CSF/PEG-G-CSF市場分析と洞察

先進国におけるがん予防の増加により、政府は早期治療を啓発するための意識的な取り組みを導入し、ラテンアメリカのバイオシミラーG-CSFの販売市場を促進しています。承認されたバイオシミラーであり、開発途上国でも費用対効果が高く容易に入手できるGrafeel、Colstim、Neukine、Filcadは、市場の大幅な成長につながるでしょう。中国とインドは、がん患者数が増加している国であり、ラテンアメリカ市場を後押しする可能性があります。したがって、バイオシミラーの使用は、オリジナルの生物学的製剤の使用と比較して患者の医療費を削減するのに役立ち、ラテンアメリカのG-CSFバイオシミラー販売市場の需要を高めます。個々のバイオシミラーの複雑な生物学的製造プロセスのため、バイオシミラーのコストはジェネリックほど安くはありません。自己免疫疾患とまれな慢性疾患の有病率の増加は、セグメント市場の成長を促進すると予想されます。

Data Bridge Market Research は、ラテンアメリカの G-CSF/PEG-G-CSF 市場は、予測期間中に 4.6% の CAGR で成長し、2030 年までに 4 億 3,097 万米ドルに達すると予測しています。この市場レポートでは、価格分析、特許分析、技術進歩についても詳細に取り上げています。

レポートメトリック	詳細
予測期間	2023年から2030年
基準年	2022
歴史的な年	2021 (2020～2015年にカスタマイズ可能)
定量単位	売上高は百万米ドル、価格は米ドル
対象セグメント	適応症（好中球減少症、腫瘍学、慢性および自己免疫疾患、血液疾患、成長調和不全症など）、用量（単剤および併用）、投与経路（静脈内、皮下）、包装（使い捨てバイアルおよびプレフィルドシリンジ）、エンドユーザー（病院および診療所、研究および学術機関、外来手術センターなど）、流通チャネル（病院薬局、オンライン薬局、小売薬局など）
対象国	メキシコ、コロンビア、ブラジル、アルゼンチン、チリ、ペルー、エクアドル、その他のラテンアメリカ諸国
対象となる市場プレーヤー	USV Private Limited, Viatris Inc., Biocon, Fresenius Kabi AG, Hangzhou Jiuyuan Gene Engineering Co., Ltd., Amgen Inc., Pfizer Inc., Sandoz International GmbH, Apotex Inc., Cadila Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., Amneal Pharmaceuticals LLC., Coherus BioSciences, Accord Healthcare, NAPP PHARMACEUTICALS LIMITED., Intas Pharmaceuticals Ltd., Mundipharma International, Teva Pharmaceutical Industries Ltd., Spectrum Pharmaceuticals, Inc., Kyowa Kirin Co., Ltd., Jiangsu Hengrui Pharmaceuticals Co., Ltd., among others.

Latin America G-CSF/ PEG-G-CSF Market Definition

Granulocyte colony-stimulating factor (G-CSF) is a medication used to treat neutropenia. This is a disease in which the number of white blood cells is lower than average and is caused by some forms of chemotherapy. The main types of G-CSF are lenograstim (Granocyte), filgrastim (Neupogen, zarzio, nivestim, accofil), long-acting (pegylated) filgrastim (pegfilgrastim, neulasta, pelmeg, ziextenco), and lipegfilgrastim (lonquex). Lenograstim is a glycosylated recombinant therapeutic agent that is chemically similar or identical to naturally occurring human granulocyte colony-stimulating factor (G-CSF). Various products include tablets and capsules and treat cancer, blood disorders, growth hormone deficiency, and chronic and autoimmune diseases.

Latin America G-CSF/ PEG-G-CSF Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:

Drivers

Growing incidences of blood cancers and cancer diseases

Cancer is a general term for many diseases that can affect any part of the body. Other terms used for cancer are malignant tumors and neoplasm. One of the characteristics of cancer is the rapid formation of abnormal cells that grow beyond normal limits and can invade neighboring parts of the body and spread to other organs; the latter process is called metastasis. Extensive metastases are the leading cause of cancer death.

Filgrastim is a granulocyte colony-stimulating factor (GCSF) that helps increase the number of neutrophils in the blood. Filgrastim and pegfilgrastim are highly used to increase white blood cells after cancer chemotherapy or radiation therapy.

Increasing cases of febrile neutropenia

Febrile neutropenia refers to fever during significant neutropenia. If a patient is neutropenic, their risk of infection may be higher than usual, and the severity of a particular infection may also be higher. Febrile neutropenia is the most common life-threatening complication of cancer treatment; its treatment is often an oncological emergency.

Febrile neutropenia is neutropenia accompanied by fever. Neutropenia refers to a decrease in the concentration of neutrophils in the blood. Neutrophils are a type of white blood cell that help fight infections as part of the immune system. The Infectious Diseases Society of America defines neutropenia as an absolute neutrophil count (ANC) of less than 1500 cells/mm3. The risk of infection and neutropenic fever increases dramatically with severe neutropenia, defined as an absolute neutrophil count (ANC) of less than 500 cells/mm3. Fever is defined as a single oral temperature greater than or equal to 101° Fahrenheit (38.3° Celsius) or a persistent temperature greater than or equal to 100.4° Fahrenheit (38.0° Celsius) or greater for one hour or longer.

Restraint

Stringent Governmental Regulations

Pharmaceutical companies developing biosimilars such as filgrastim face a major challenge in the approval process for their products. Each country has a different approval process for all drugs, treatments, vaccines, and medical devices. However, these approval procedures are difficult to follow. This is due to the various regulations and evidence required to prove the effectiveness and safety of the product.

European Medicines Agency regulatory requirements ensure the same high quality, safety, and efficacy standards for biosimilars as for originator biologicals. They also include a rigorous comparability exercise with the reference product but are not universally accepted by regulatory bodies outside the European Union (EU). It should be noted that 'similar biologics' approved in India, 'biogenerics' approved in Iran, 'medicamento biológico similares' approved in Argentina, and non-originator biologicals approved in South Africa might not have been authorized if they had been subjected to the strict regulatory processes required for approval of biosimilars in the EU.

Opportunity

The use of biosimilars helps reduce healthcare costs for patients

Biosimilars have the potential to fundamentally change healthcare by providing more affordable, equally effective treatments for patients and providing more treatment options for physicians. Developing biosimilars requires rigorous analysis to demonstrate their equivalence to the reference product and ensure no clinically meaningful differences in their safety, efficacy, and purity. As a result, health systems can channel long-term savings into overall improvements in patient care. To help create a thriving biosimilar market and ensure patient access, policymakers can take steps to reduce or eliminate the cost of biosimilars and encourage physicians to prescribe biosimilars compared to Europe.

Challenge

Multiple side effects of G-CSF

Granulocyte colony-stimulating factor (G-CSF) is a drug used to treat neutropenia, a disorder in which certain forms of chemotherapy cause a lower-than-average number of white blood cells. G-CSF is a type of growth factor that makes the bone marrow produce more white blood cells to reduce the risk of infection after some types of cancer treatment. But there are multiple side effects of G-CSF, such as bone or muscle pain, Bruising, bleeding gums or nosebleeds, diarrhea, high temperature (fever), breathlessness and looking pale, sore mouth, throat, gut and back passage, and, among others. These side effects can be seen in more than 10 in 100 people (more than 10%).

According to a study performed by NCBI, most normal donors receiving G-CSF experience side effects, but these are mild to moderate in degree. Ninety percent of donors experienced some side effects of G-CSF. The most frequent effects noted were bone pain (83%), headache (39%), body aches (23%), fatigue (14%), and nausea and vomiting (12%), which is expected to act as a challenge for market growth.

Post-COVID-19 Impact on Latin America G-CSF/ PEG-G-CSF Market

The COVID-19 pandemic has had somewhat positive impact on the G-CSF/ PEG-G-CSF market. The pandemic has imposed new norms and regulations, such as social distancing and lockdowns, to prevent the spread of the virus. As a result, people all over the world were forced to stay at home, which led to new trends such as work at home. This stay at home has led decrease in diagnosis and prognosis of diseases. The increased focus on self-care, exercise and health has helped fitness apps and platforms gain significant traction in the wake of the pandemic.

Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities and product launch and strategic partnerships to improve the technology and test results involved in the transplant diagnostics market.

Recent Developments

In July 2018, Accord Healthcare, a subsidiary of Intas Pharmaceuticals Ltd., launched a pegfilgrastim biosimilar across Europe after being given Green Light for Pelgraz® (pegfilgrastim) by CHMP (Committee for Medicinal Products for Human Use). This product launched helped the company to expand their business across Europe.
In March 2022, Kashiv Biosciences announced the approval of its Biologics License Application (BLA) for filgrastim-ayow, a biosimilar referencing Neupogen by U.S. Food and Drug Administration (FDA). The product is marketed under the proprietary name RELEUKO.

Latin America G-CSF/ PEG-G-CSF Market Scope

Latin America G-CSF/ PEG-G-CSF market is segmented into indication, dosage, route of administration, packaging, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

LATIN AMERICA G-CSF / PEG-G-CSF MARKET, BY INDICATION

好中球減少症
腫瘍学
慢性疾患および自己免疫疾患
血液疾患
成長ホルモン欠乏症
その他

適応症に基づいて、ラテンアメリカの G-CSF/PEG-G-CSF は、好中球減少症、腫瘍学、慢性および自己免疫疾患、血液疾患、成長ホルモン欠乏症、その他にさらに分類されます。

ラテンアメリカのG-CSF / PEG-G-CSF市場（用量別）

単核症
組み合わせ

投与量に基づいて、ラテンアメリカの G-CSF/PEG-G-CSF はさらに単一剤と併用剤に分類されます。

ラテンアメリカのG-CSF / PEG-G-CSF市場（投与経路別）

静脈内
皮下

投与経路に基づいて、ラテンアメリカの G-CSF/PEG-G-CSF はさらに静脈内と皮下に分けられます。

ラテンアメリカのG-CSF / PEG-G-CSF市場（包装別）

使い捨てバイアル
プレフィルドシリンジ

ラテンアメリカの G-CSF/PEG-G-CSF は、パッケージに基づいて、さらに使い捨てバイアルと充填済みシリンジに分類されます。

ラテンアメリカのG-CSF / PEG-G-CSF市場（エンドユーザー別）

病院・クリニック
研究・学術機関
外来手術センター
その他

エンドユーザーに基づいて、ラテンアメリカの G-CSF/PEG-G-CSF は、病院や診療所、研究・学術機関、外来手術センターなどにさらに細分化されます。

ラテンアメリカのG-CSF / PEG-G-CSF市場（流通チャネル別）

病院薬局
オンライン薬局
小売薬局
その他

流通チャネルに基づいて、ラテンアメリカの G-CSF/PEG-G-CSF はさらに病院薬局、オンライン薬局、小売薬局、その他に分類されます。

ラテンアメリカ G-CSF/PEG-G-CSF 市場地域分析/洞察

ラテンアメリカの G-CSF/PEG-G-CSF 市場が分析され、国、適応症、投与量、投与経路、パッケージ、エンドユーザー、流通チャネルに基づいて市場規模の情報が提供されます。

ラテンアメリカの G-CSF/PEG-G-CSF 市場は、メキシコ、コロンビア、ブラジル、アルゼンチン、チリ、ペルー、エクアドル、その他の LATAM 諸国で構成されています。

メキシコは、高いGDPを誇る最大の消費者市場に主要な市場プレーヤーが存在するため、優位に立っています。

レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータポイントは、各国の市場シナリオを予測するために使用される主要な指標の一部です。また、国別データの予測分析を提供する際には、ラテンアメリカのブランドの存在と可用性、地元および国内ブランドとの競争が激しいか少ないために直面する課題、販売チャネルの影響も考慮されます。

競争環境とラテンアメリカの G-CSF/PEG-G-CSF 市場シェア分析

ラテンアメリカの G-CSF/PEG-G-CSF 市場の競争状況は、競合他社ごとに詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品試験パイプライン、製品の承認、特許、製品の幅と幅、アプリケーションの優位性、技術ライフライン曲線などがあります。提供されている上記のデータポイントは、ラテンアメリカの G-CSF/PEG-G-CSF 市場への会社の重点にのみ関連しています。

この市場で取引を行っている大手企業としては、USV Private Limited、Viatris Inc.、Biocon、Fresenius Kabi AG、Hangzhou Jiuyuan Gene Engineering Co., Ltd.、Amgen Inc.、Pfizer Inc.、Sandoz International GmbH、Apotex Inc.、Cadila Pharmaceuticals、Dr. Reddy's Laboratories Ltd.、Amneal Pharmaceuticals LLC.、Coherus BioSciences、Accord Healthcare、NAPP PHARMACEUTICALS LIMITED.、Intas Pharmaceuticals Ltd.、Mundipharma International、Teva Pharmaceutical Industries Ltd.、Spectrum Pharmaceuticals, Inc.、Kyowa Kirin Co., Ltd.、Jiangsu Hengrui Pharmaceuticals Co., Ltd. などがあります。

SKU-69580

世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする

画像をクリックすると拡大します

インタラクティブなデータ分析ダッシュボード
成長の可能性が高い機会のための企業分析ダッシュボード
カスタマイズとクエリのためのリサーチアナリストアクセス
インタラクティブなダッシュボードによる競合分析
最新ニュース、更新情報、トレンド分析
包括的な競合追跡のためのベンチマーク分析のパワーを活用

デモのリクエスト

表のリスト

TABLE 1 BELOW ARE THE RULES AND REGULATIONS TO GET APPROVAL FOR USE IN THE MARKET:

TABLE 2 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 3 LATIN AMERICA NEUTROPENIA IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 LATIN AMERICA NEUTROPENIA IN G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 5 LATIN AMERICA ONCOLOGY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 LATIN AMERICA ONCOLOGY IN G-CSF/ PEG-G-CSF MARKET, BY INDICATION, 2021-2030 (USD MILLION)

TABLE 7 LATIN AMERICA CHRONIC AND AUTO IMMUNE DISEASES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 LATIN AMERICA BLOOD DISORDERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 9 LATIN AMERICA GROWTH HORMONE DEFICIENCY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 LATIN AMERICA OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY DOSAGE, 2020-2029 (USD MILLION)

TABLE 12 LATIN AMERICA MONO IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 LATIN AMERICA COMBINATION IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 15 LATIN AMERICA SUBCUTANEOUS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 LATIN AMERICA INTRAVENOUS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY PACKAGING, 2020-2029 (USD MILLION)

TABLE 18 LATIN AMERICA PRE FILLED SYRINGES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 LATIN AMERICA SINGLE USE VIALS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 21 LATIN AMERICA HOSPITALS AND CLINICS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 LATIN AMERICA RESEARCH & ACADEMIC INSTITUTES IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 LATIN AMERICA AMBULATORY SURGICAL CENTERS IN G-CSF/ PEG-G-CSFMARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 LATIN AMERICA OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 25 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 26 LATIN AMERICA HOSPITALS PHARMACY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 LATIN AMERICA RETAIL PHARMACY IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 LATIN AMERICA ONLINE PHARMACY IN G-CSF/ PEG-G-CSFMARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 LATIN AMERICA OTHERS IN G-CSF/ PEG-G-CSF MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 LATAM G-CSF / PEG-G-CSF MARKET, 2020-2030 (USD MILLION)

TABLE 31 LATAM G-CSF / PEG-G-CSF MARKET, 2020-2030 (USD MILLION)

TABLE 32 LATAM G-CSF / PEG-G-CSF MARKET, BY COUNTRY, 2020-2030 (USD MILLION)

TABLE 33 LATAM G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 34 LATAM NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 35 LATAM ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 36 LATAM G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)

TABLE 37 LATAM G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)

TABLE 38 LATAM G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)

TABLE 39 LATAM G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)

TABLE 40 LATAM G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 41 MEXICO G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 42 MEXICO NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 43 MEXICO ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 44 MEXICO G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)

TABLE 45 MEXICO MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 46 MEXICO G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)

TABLE 47 MEXICO SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 48 MEXICO INTRAVENOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 49 MEXICO G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)

TABLE 50 MEXICO PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 51 MEXICO G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)

TABLE 52 MEXICO HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 53 MEXICO HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 54 MEXICO HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 55 MEXICO RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 56 MEXICO RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 57 MEXICO RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 58 MEXICO AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 59 MEXICO AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 60 MEXICO AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 61 MEXICO G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 62 MEXICO HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 63 MEXICO HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 64 MEXICO HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 65 MEXICO RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 66 MEXICO RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 67 MEXICO RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 68 MEXICO ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 69 MEXICO ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 70 MEXICO ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 71 COLUMBIA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 72 COLUMBIA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 73 COLUMBIA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 74 COLUMBIA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)

TABLE 75 COLUMBIA MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 76 COLUMBIA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)

TABLE 77 COLUMBIA SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 78 COLUMBIA G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)

TABLE 79 COLUMBIA PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 80 COLUMBIA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)

TABLE 81 COLUMBIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 82 COLUMBIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 83 COLUMBIA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 84 COLUMBIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 85 COLUMBIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 86 COLUMBIA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 87 COLUMBIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 88 COLUMBIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 89 COLUMBIA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 90 COLUMBIA G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 91 COLUMBIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 92 COLUMBIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 93 COLUMBIA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 94 COLUMBIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 95 COLUMBIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 96 COLUMBIA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 97 COLUMBIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 98 COLUMBIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 99 COLUMBIA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 100 BRAZIL G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 101 BRAZIL NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 102 BRAZIL ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 103 BRAZIL G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)

TABLE 104 BRAZIL MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 105 BRAZIL G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)

TABLE 106 BRAZIL SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 107 BRAZIL G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)

TABLE 108 BRAZIL PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 109 BRAZIL G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)

TABLE 110 BRAZIL HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 111 BRAZIL HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 112 BRAZIL HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 113 BRAZIL RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 114 BRAZIL RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 115 BRAZIL RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 116 BRAZIL AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 117 BRAZIL AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 118 BRAZIL AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 119 BRAZIL G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 120 BRAZIL HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 121 BRAZIL HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 122 BRAZIL HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 123 BRAZIL RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 124 BRAZIL RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 125 BRAZIL RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 126 BRAZIL ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 127 BRAZIL ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 128 BRAZIL ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 129 ARGENTINA G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 130 ARGENTINA NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 131 ARGENTINA ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 132 ARGENTINA G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)

TABLE 133 ARGENTINA MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 134 ARGENTINA G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)

TABLE 135 ARGENTINA SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 136 ARGENTINA INTRAVENOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 137 ARGENTINA G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)

TABLE 138 ARGENTINA PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 139 ARGENTINA G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)

TABLE 140 ARGENTINA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 141 ARGENTINA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 142 ARGENTINA HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 143 ARGENTINA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 144 ARGENTINA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 145 ARGENTINA RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 146 ARGENTINA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 147 ARGENTINA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 148 ARGENTINA AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 149 ARGENTINA G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 150 ARGENTINA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 151 ARGENTINA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 152 ARGENTINA HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 153 ARGENTINA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 154 ARGENTINA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 155 ARGENTINA RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 156 ARGENTINA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 157 ARGENTINA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 158 ARGENTINA ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 159 CHILE G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 160 CHILE NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 161 CHILE ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 162 CHILE G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)

TABLE 163 CHILE MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 164 CHILE G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)

TABLE 165 CHILE SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 166 CHILE G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)

TABLE 167 CHILE PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 168 CHILE G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)

TABLE 169 CHILE HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 170 CHILE HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 171 CHILE HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 172 CHILE RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 173 CHILE RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 174 CHILE RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 175 CHILE AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 176 CHILE AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 177 CHILE AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 178 CHILE G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 179 CHILE HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 180 CHILE HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 181 CHILE HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 182 CHILE RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 183 CHILE RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 184 CHILE RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 185 CHILE ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 186 CHILE ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 187 CHILE ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 188 PERU G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 189 PERU NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 190 PERU ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 191 PERU G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)

TABLE 192 PERU MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 193 PERU G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)

TABLE 194 PERU SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 195 PERU INTRAVENOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 196 PERU G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)

TABLE 197 PERU PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 198 PERU SINGLE USE VIALS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 199 PERU G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)

TABLE 200 PERU HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 201 PERU HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 202 PERU HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 203 PERU RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 204 PERU RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 205 PERU RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 206 PERU AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 207 PERU AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 208 PERU AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 209 PERU G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 210 PERU HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 211 PERU HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 212 PERU HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 213 PERU RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 214 PERU RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 215 PERU RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 216 PERU ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 217 PERU ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 218 PERU ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 219 ECUADOR G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 220 ECUADOR NEUTROPENIA IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 221 ECUADOR ONCOLOGY IN G-CSF / PEG-G-CSF MARKET, BY INDICATION, 2020-2030 (USD MILLION)

TABLE 222 ECUADOR G-CSF / PEG-G-CSF MARKET, BY DOSAGE, 2020-2030 (USD MILLION)

TABLE 223 ECUADOR MONO IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 224 ECUADOR G-CSF / PEG-G-CSF MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030 (USD MILLION)

TABLE 225 ECUADOR SUBCUTANEOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 226 ECUADOR INTRAVENOUS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 227 ECUADOR G-CSF / PEG-G-CSF MARKET, BY PACKAGING, 2020-2030 (USD MILLION)

TABLE 228 ECUADOR PRE FILLED SYRINGES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 229 ECUADOR G-CSF / PEG-G-CSF MARKET, BY END USER, 2020-2030 (USD MILLION)

TABLE 230 ECUADOR HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 231 ECUADOR HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 232 ECUADOR HOSPITAL AND CLINICS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 233 ECUADOR RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 234 ECUADOR RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 235 ECUADOR RESEARCH AND ACADEMIC INSTITUTES IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 236 ECUADOR AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 237 ECUADOR AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 238 ECUADOR AMBULATORY SURGICAL CENTERS IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 239 ECUADOR G-CSF / PEG-G-CSF MARKET, BY DISTRIBUTION CHANNEL, 2020-2030 (USD MILLION)

TABLE 240 ECUADOR HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 241 ECUADOR HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 242 ECUADOR HOSPITAL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 243 ECUADOR RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 244 ECUADOR RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 245 ECUADOR RETAIL PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

TABLE 246 ECUADOR ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 (USD MILLION)

TABLE 247 ECUADOR ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 ASP (USD)

TABLE 248 ECUADOR ONLINE PHARMACY IN G-CSF / PEG-G-CSF MARKET, BY BRAND, 2020-2030 VOLUME (UNITS)

図表一覧

FIGURE 1 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: SEGMENTATION

FIGURE 2 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: DATA TRIANGULATION

FIGURE 3 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: DROC ANALYSIS

FIGURE 4 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: LATIN AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: DBMR MARKET POSITION GRID

FIGURE 8 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: MARKET END USER COVERAGE GRID

FIGURE 9 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: SEGMENTATION

FIGURE 11 THE INCREASE IN CANCER PROPHYLAXIS IN DEVELOPED COUNTRIES AND INITIATIVES TAKEN BY GOVERNMENTS ARE TO DRIVE THE LATIN AMERICA G-CSF / PEG-G-CSF MARKET FROM 2023 TO 2030

FIGURE 12 NEUTROPENIA SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE LATIN AMERICA G-CSF / PEG-G-CSF MARKET IN 2023 & 2030

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE LATIN AMERICA G-CSF / PEG-G-CSF MARKET

FIGURE 14 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, 2022

FIGURE 15 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, 2021-2030 (USD MILLION)

FIGURE 16 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, CAGR (2022-2029)

FIGURE 17 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY INDICATION CATEGORY, LIFELINE CURVE

FIGURE 18 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, 2022

FIGURE 19 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, 2021-2030 (USD MILLION)

FIGURE 20 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, CAGR (2023-2030)

FIGURE 21 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY DOSAGE, LIFELINE CURVE

FIGURE 22 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, 2022

FIGURE 23 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, 2021-2030 (USD MILLION)

FIGURE 24 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2023-2030)

FIGURE 25 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 26 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, 2022

FIGURE 27 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, 2021-2030 (USD MILLION)

FIGURE 28 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, CAGR (2023-2030)

FIGURE 29 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY PACKAGING, LIFELINE CURVE

FIGURE 30 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY END USER, 2022

FIGURE 31 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY END USER, 2021-2030 (USD MILLION)

FIGURE 32 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY END USER, CAGR (2023-2030)

FIGURE 33 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY END USER, LIFELINE CURVE

FIGURE 34 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, 2022

FIGURE 35 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, 2021-2030 (USD MILLION)

FIGURE 36 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, CAGR (2023-2030)

FIGURE 37 LATIN AMERICA G-CSF/ PEG-G-CSF MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 38 LATIN AMERICA G-CSF/PEG-G-CSF MARKET: SNAPSHOT (2022)

FIGURE 39 LATIN AMERICA G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022)

FIGURE 40 LATIN AMERICA G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022 & 2030)

FIGURE 41 LATIN AMERICA G-CSF/PEG-G-CSF MARKET: BY COUNTRY (2022 & 2030)

FIGURE 42 LATIN AMERICA G-CSF/PEG-G-CSF MARKET: BY INDICATION (2023-2030)

FIGURE 43 LATIN AMERICA G-CSF / PEG-G-CSF MARKET: COMPANY SHARE 2022 (%)

詳細情報を見る

調査方法

データ収集と基準年分析は、大規模なサンプルサイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。

DBMR 調査チームが使用する主要な調査方法は、データマイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データモデルには、ベンダーポジショニンググリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニンググリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダーシェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。

カスタマイズ可能

Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータスタイルでいくつでも追加できます。当社のアナリストチームは、粗い生の Excel ファイルピボットテーブル (ファクトブック) でデータを提供したり、レポートで利用可能なデータセットからプレゼンテーションを作成するお手伝いをしたりすることもできます。

Frequently Asked Questions

At what growth rate will the market be projected to grow during the forecast period of 2023 to 2030?

The Latin America G-CSF/ PEG-G-CSF Market is projected to grow at a CAGR of 4.6% during the forecast period by 2030.

What will be the market value in the future?

The future market value of the Latin America G-CSF/ PEG-G-CSF Market is expected to reach USD 430.97 million by 2030.

Who are the major players operating in the market?

The major players in the Latin America G-CSF/ PEG-G-CSF Market are USV Private Limited, Viatris Inc., Biocon, Fresenius Kabi AG, Hangzhou Jiuyuan Gene Engineering Co., Ltd., Amgen Inc., Pfizer Inc., Sandoz International GmbH, Apotex Inc., Cadila Pharmaceuticals, Dr. Reddy’s Laboratories Ltd., etc.

Which countries data are covered in the report?

The countries covered in the Latin America G-CSF/ PEG-G-CSF Market are Mexico, Columbia, Brazil, Argentina, Chile, Peru, Ecuador, Rest of LATAM.

予測期間	2024 –2030
市場規模（基準年）	USD MILLION Request
Market Size (Forecast Year)	USD 430.97
CAGR	4.60 %
主要市場プレーヤー	Dummy1 Dummy2 Dummy3 Dummy4 Dummy5 Request For Unlock

ラテンアメリカの G-CSF/PEG-G-CSF 市場 – 業界動向と 2030 年までの予測

ラテンアメリカの G-CSF/PEG-G-CSF 市場 – 業界動向と 2030 年までの予測